REVIEW
1694  Nutritional assessment in patients with liver cirrhosis
   Haj Ali S, Abu Sneineh A, Hasweh R

MINIREVIEWS
1704  Non-alcoholic fatty liver disease: Is surgery the best current option and can novel endoscopy play a role in the future?
   Mandour MO, El-Hassan M, Elkomi RM, Oben JA
1718  Therapies for non-alcoholic fatty liver disease: A 2022 update
   Shen K, Singh AD, Modaresi Esfeh J, Wakim-Fleming J
1730  Bile acids as drivers and biomarkers of hepatocellular carcinoma
   Colosimo S, Tomlinson JW
1739  Approach to persistent ascites after liver transplantation
   Ostojic A, Petrovic I, Silovski H, Kosuta I, Sremac M, Mrzljak A

ORIGINAL ARTICLE

Case Control Study
1747  Alcohol intake is associated with a decreased risk of developing primary biliary cholangitis

Retrospective Cohort Study
1757  Positive autoantibodies in living liver donors
   Loh J, Hashimoto K, Kwon CHD, Fujiki M, Modaresi Esfeh J

Retrospective Study
1767  Decrease in liver cancer incidence rates in Bamako, Mali over 28 years of population-based cancer registration (1987-2015)
1778  Modified preoperative score to predict disease-free survival for hepatocellular carcinoma patients with surgical resections
1790  Liver magnetic resonance imaging for evaluation of response to treatment after stereotactic body radiation therapy of hepatocellular carcinoma
## Contents

### Observational Study

**1804** Heredity hemochromatosis: Temporal trends, sociodemographic characteristics, and independent risk factor of hepatocellular cancer – nationwide population-based study  
*Haider MB, Al Shihi A, Chaudhary AJ, Haider SM, Edhi AI*

### CASE REPORT

**1817** A retrospective study on use of palliative care for patients with alcohol related end stage liver disease in United States  
*Gupta K, Hans B, Khan A, Sohail SH, Kapuria D, Chang C*

### LETTER TO THE EDITOR

**1830** Primary hepatic leiomyosarcoma: A case report and literature review  
*Ahmed H, Bari H, Nisar Sheikh U, Basheer MI*

**1840** Analysis of hepatitis C virus-positive organs in liver transplantation.  
*Legaz I, Muro M*
## Contents

### ABOUT COVER
Editorial Board Member of *World Journal of Hepatology*, Mohit Girotra, MD, FASGE, FACP, Consultant Gastroenterologist and Therapeutic Endoscopist, Digestive Health Institute, Swedish Medical Center, Seattle, WA 98104, United States. girotra.mohit@gmail.com

### AIMS AND SCOPE
The primary aim of *World Journal of Hepatology (WJH, World J Hepatol)* is to provide scholars and readers from various fields of hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

*WJH* mainly publishes articles reporting research results and findings obtained in the field of hepatology and covering a wide range of topics including chronic cholestatic liver diseases, cirrhosis and its complications, clinical alcoholic liver disease, drug induced liver disease autoimmune, fatty liver disease, genetic and pediatric liver diseases, hepatocellular carcinoma, hepatic stellate cells and fibrosis, liver immunology, liver regeneration, hepatic surgery, liver transplantation, biliary tract pathophysiology, non-invasive markers of liver fibrosis, viral hepatitis.

### INDEXING/ABSTRACTING
The *WJH* is now abstracted and indexed in PubMed, PubMed Central, Emerging Sources Citation Index (Web of Science), Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 edition of Journal Citation Reports® cites the 2021 Journal Citation Indicator (JCI) for *WJH* as 0.52. The *WJH*’s CiteScore for 2021 is 3.6 and Scopus CiteScore rank 2021: Hepatology is 42/70.

### RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Yi-Xuan Cai; Production Department Director: Xiang Li; Editorial Office Director: Xiang Li.

<table>
<thead>
<tr>
<th>NAME OF JOURNAL</th>
<th>World Journal of Hepatology</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISSN</td>
<td>ISSN 1948-5182 (online)</td>
</tr>
<tr>
<td>LAUNCH DATE</td>
<td>October 31, 2009</td>
</tr>
<tr>
<td>FREQUENCY</td>
<td>Monthly</td>
</tr>
<tr>
<td>EDITORS-IN-CHIEF</td>
<td>Nikolaos Pyrsopoulos, Ke-Qin Hu, Koo Jeong Kang</td>
</tr>
<tr>
<td>PUBLICATION DATE</td>
<td>September 27, 2022</td>
</tr>
<tr>
<td>COPYRIGHT</td>
<td>© 2022 Baishideng Publishing Group Inc</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>INSTRUCTIONS TO AUTHORS</th>
<th><a href="https://www.wjgnet.com/bpg/gerinfo/204">https://www.wjgnet.com/bpg/gerinfo/204</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>GUIDELINES FOR ETHICS DOCUMENTS</td>
<td><a href="https://www.wjgnet.com/bpg/gerinfo/287">https://www.wjgnet.com/bpg/gerinfo/287</a></td>
</tr>
<tr>
<td>GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH</td>
<td><a href="https://www.wjgnet.com/bpg/gerinfo/240">https://www.wjgnet.com/bpg/gerinfo/240</a></td>
</tr>
<tr>
<td>PUBLICATION ETHICS</td>
<td><a href="https://www.wjgnet.com/bpg/gerinfo/288">https://www.wjgnet.com/bpg/gerinfo/288</a></td>
</tr>
<tr>
<td>PUBLICATION MISCONDUCT</td>
<td><a href="https://www.wjgnet.com/bpg/gerinfo/208">https://www.wjgnet.com/bpg/gerinfo/208</a></td>
</tr>
<tr>
<td>ARTICLE PROCESSING CHARGE</td>
<td><a href="https://www.wjgnet.com/bpg/gerinfo/242">https://www.wjgnet.com/bpg/gerinfo/242</a></td>
</tr>
<tr>
<td>STEPS FOR SUBMITTING MANUSCRIPTS</td>
<td><a href="https://www.wjgnet.com/bpg/gerinfo/239">https://www.wjgnet.com/bpg/gerinfo/239</a></td>
</tr>
<tr>
<td>ONLINE SUBMISSION</td>
<td><a href="https://www.f6publishing.com">https://www.f6publishing.com</a></td>
</tr>
</tbody>
</table>

© 2022 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
E-mail: bpgoffice@wjgnet.com  https://www.wjgnet.com
Analysis of hepatitis C virus-positive organs in liver transplantation.

Isabel Legaz, Manuel Muro

Isabel Legaz, Department of Legal and Forensic Medicine, Biomedical Research Institute, Regional Campus of International Excellence "Campus Mare Nostrum", Faculty of Medicine, University of Murcia, Murcia 30100, Spain

Manuel Muro, Department of Immunology Service, Instituto Murciano de Investigación Biosanitaria, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia 30120, Spain

Corresponding author: Isabel Legaz, PhD, Senior Lecturer, Department of Legal and Forensic Medicine, Biomedical Research Institute, Regional Campus of International Excellence "Campus Mare Nostrum", Faculty of Medicine, University of Murcia, Espinardo, Murcia 30100, Spain. isalegaz@um.es

Abstract

The authors of this study note that in liver transplantation (LT), the survival rates of hepatitis C virus (HCV)-positive donors and HCV-negative receivers are comparable to those of HCV-negative donors and recipients. Direct-acting antiviral (DAA) therapies have nearly 100% effectiveness in treating HCV. Between 2006 and 2016, the percentages of HCV-positive patients on the waiting list and HCV-positive LT recipients fell by 8.2 percent and 7.6 percent, respectively. Records from April 1, 2014, in which the donor and receiver were both at least 18 years old and had a positive HCV status, were the only ones eligible for the study. The analysis for this study was restricted to the first transplant recorded for each patient using a data element that documented the number of prior transplants for each recipient, although some recipients appeared multiple times in the data set. HCV-positive recipients or people with fulminant hepatic failure were the main beneficiaries of primary biliary cirrhosis among HCV-positive donors. However, there is still a reticence to use HCV-positive donor organs in HCV recipients due to clinical and ethical considerations. Similar survival rates between HCV-positive donors and recipients and HCV-negative donors and receivers illustrate the efficacy of these DAA regimens.

Key Words: Hepatitis C virus; Liver transplant; Graft survival; United network for organ sharing; Direct-acting antiviral

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Core Tip: The scarcity of viable organs, which is quite limited, the waiting lists that reflect chronicity and the increase in time to transplantation, and the rate of physical deterioration resulting in death while waiting for a helpful organ for transplantation, promote the search for new ways, strategies, and protocols to increase the group of donors acceptable for transplantation, such as donors in asystole, donors with tumor processes, or donors with previous infection. The application of antivirals against the hepatitis C virus (HCV), with unprecedented success in the elimination of the pathogen, has led to the use of HCV-positive donors as optimal donors for HCV-negative recipients, with survival similar to that of both HCV-negative donors and recipients, which supports the use of these HCV-positive donors without restrictions.

Citation: Legaz I, Muro M. Analysis of hepatitis C virus-positive organs in liver transplantation. World J Hepatol 2022; 14(9): 1840-1843
URL: https://www.wjgnet.com/1948-5182/full/v14/i9/1840.htm
DOI: https://dx.doi.org/10.4254/wjh.v14.i9.1840

TO THE EDITOR

We have read with great attention and particular interest the review by Dhaliwal A et al[1] entitled 'Impact of the use of positive organs for hepatitis C in liver transplantation: Analysis of the database of the United Network for Organ Sharing'. The study noted that the survival rates of hepatitis C virus (HCV)-positive donors and -negative recipients following liver transplantation (LT) are comparable to those of HCV-negative donors and recipients. On the other hand, direct-acting antiviral (DAA) therapies have a nearly 100% effectiveness rate in the treatment of HCV infection[2-4].

The proportions of HCV-positive waiting list patients and HCV-positive LT recipients decreased by 8.2% and 7.6%, respectively, between 2006 and 2016[5]. HCV recurrence post-LT was the most frequent reason for graft failure prior to the availability of DAA treatment and significantly decreased recipient survival in patients with HCV positivity compared to HCV-negative patients[6,7]. This HCV recurrence significantly impacted the allocation of HCV-positive donors, severely underutilizing these organs, especially in HCV-negative recipients. Due to the strong potency and low risk of side effects of this new generation of DAAs, there is an increasing propensity to use organs from HCV-positive donors, especially those with high viral loads[8,9]. The United Network for Organ Sharing (UNOS) database was utilized in this study to compare the survival rates of HCV-negative donors and recipients with those of HCV-positive donors and recipients[10].

The authors of this intriguing study used information from the UNOS registry, which includes information on every transplant in the country. Records from April 1, 2014, in which the donor and receiver were both at least 18 years old and had a positive HCV status, were the only ones eligible for the study. Although some recipients appeared many times in the data set, the analysis for this study was limited to the first transplant recorded for each patient using a data element that tracked the number of prior transplants for each recipient. The primary outcome was overall survival time as of the most recent patient follow-up on September 7, 2018, with death being indicated by the composite indicator of death and censoring for those who did not die throughout the trial period. The authors used log-rank tests and group survival estimates at various time points of monitoring after transplantation to compare overall survival between groups. The investigation comprised a total of 24512 transplants, with 253 people who received transplants from positive donors to negative recipients. The duration of cold ischemia was comparable across all groups. Following cirrhosis caused by HCV, cirrhosis caused by non-alcoholic steatohepatitis, and hepatoma as the most frequent primary diagnoses were alcoholic cirrhosis/acute alcoholic hepatitis. Looking at survival rates at 1-year, 2-year, and 3-year intervals revealed that the particular group with a positive donor and negative recipient had lower survival rates than the other three groups (negative donor and positive recipient; positive donor and negative recipient; positive donor and positive recipient) which were all close together.

HCV-positive recipients or people with fulminant hepatic failure were the main beneficiaries of primary biliary cirrhosis among HCV-positive donors. However, due to clinical and ethical considerations, there is still reticence to use organs from HCV-positive donors in HCV-positive recipients. In a study of 99 recipients of liver grafts from HCV-positive donors, Lai et al[11] found that HCV-positive donor graft recipients had significantly higher unadjusted rates of advanced fibrosis at 1 and 3 years than HCV-positive donor graft recipients. According to Kharpa et al's study of 29 HCV-positive donor liver graft recipients, they exhibited significantly greater fibrosis and a faster rate of development[12].

However, studies of single-center experiences and large public databases, such as UNOS and the Scientific Registry of Transplant Recipients, have shown that recipients of livers from HCV-positive and HCV-negative donors had the same results since the introduction of DAAs[13-15].

It should be mentioned that there is currently no recognized procedure. The people who participated in this research were in preventive therapy. The information was obtained from a large population-
based study based on a well-known UNOS database that included many Americans. The authors concluded that the survival rates of HCV-positive donors and recipients and HCV-negative donors and receivers are identical. More studies should be carried out in the future in more national and international transplant registries to confirm these points.

FOOTNOTES

Author contributions: Muro M and Legaz I designed the research, performed the research, and wrote and revised the letter.

Conflict-of-interest statement: There is no conflict of interest to disclose.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: Spain

ORCID number: Isabel Legaz 0000-0002-1140-4313; Manuel Muro 0000-0001-9987-0994.

S-Editor: Wang LL
L-Editor: Wang TQ
P-Editor: Wang LL

REFERENCES


